Bicycle Therapeutics plc (NASDAQ:BCYC – Get Free Report) was the recipient of a significant decrease in short interest in July. As of July 31st, there was short interest totalling 2,070,000 shares, a decrease of 23.0% from the July 15th total of 2,690,000 shares. Based on an average trading volume of 283,600 shares, the days-to-cover ratio is presently 7.3 days.
Bicycle Therapeutics Trading Down 1.3 %
Shares of BCYC stock traded down $0.30 during trading hours on Friday, reaching $22.42. The company had a trading volume of 84,866 shares, compared to its average volume of 328,279. The company has a 50 day moving average of $22.30 and a 200 day moving average of $22.63. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.42 and a quick ratio of 10.42. The firm has a market cap of $959.11 million, a price-to-earnings ratio of -5.04 and a beta of 0.94. Bicycle Therapeutics has a 1-year low of $12.54 and a 1-year high of $27.24.
Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.77) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.33. Bicycle Therapeutics had a negative return on equity of 49.35% and a negative net margin of 404.14%. The company had revenue of $9.36 million during the quarter, compared to analysts’ expectations of $6.13 million. The company’s revenue was down 17.9% compared to the same quarter last year. On average, equities research analysts anticipate that Bicycle Therapeutics will post -4.44 EPS for the current year.
Analyst Ratings Changes
Get Our Latest Analysis on BCYC
Insider Activity
In other news, CEO Kevin Lee sold 3,194 shares of the stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $19.64, for a total transaction of $62,730.16. Following the transaction, the chief executive officer now owns 384,076 shares in the company, valued at approximately $7,543,252.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 4,555 shares of company stock worth $89,460 over the last 90 days. 8.50% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. grew its holdings in Bicycle Therapeutics by 71.4% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,859 shares of the company’s stock worth $171,000 after acquiring an additional 2,858 shares during the period. PNC Financial Services Group Inc. bought a new position in shares of Bicycle Therapeutics during the 4th quarter worth approximately $137,000. PDS Planning Inc bought a new position in shares of Bicycle Therapeutics during the 1st quarter worth approximately $210,000. XTX Topco Ltd purchased a new stake in shares of Bicycle Therapeutics during the 2nd quarter worth approximately $206,000. Finally, Natixis Advisors LLC purchased a new stake in shares of Bicycle Therapeutics during the 2nd quarter worth approximately $261,000. 86.15% of the stock is currently owned by institutional investors.
Bicycle Therapeutics Company Profile
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.
Read More
- Five stocks we like better than Bicycle Therapeutics
- How to Use the MarketBeat Dividend Calculator
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Manufacturing Stocks Investing
- MarketBeat Week in Review – 8/12 – 8/16
- What is the Shanghai Stock Exchange Composite Index?
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.